Cardiovascular, Pulmonary and Renal Pathology

Bone Marrow-Derived Cells Contribute to Fibrosis in the Chronically Failing Heart

Po-Yin Chu,* Justin Mariani,* Samara Finch,* Julie R. McMullen,† Junichi Sadoshima,‡ Tanneale Marshall,* and David M. Kaye*

From the Heart Failure Research Group,* and Cardiac Hypertrophy Laboratory,† Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia; and the Departments of Cell Biology and Molecular Medicine,‡ New Jersey Medical School, Newark, New Jersey

Cardiac fibrosis contributes significantly to the phenotype of the chronically failing heart. It is not clear whether in this setting the fibrosis is contributed by native cardiac fibroblasts or alternatively by recruitment of cells arising from the bone marrow. We aimed to determine the contribution of bone marrow-derived cells to cardiac fibrosis in the failing heart and to investigate potentially contributing cytokines. Bone marrow-derived fibrocyte recruitment to the failing heart was studied in a transgenic (Mst1 mice) model of dilated cardiomyopathy. In conjunction, we examined the role of stromal-derived factor-1 (SDF-1), a key chemoattractant, by assessing myocardial expression and secretion by cardiomyocytes and in clinical samples. Bone marrow-derived cells were recruited in significantly greater numbers in Mst1 versus control mice (P < 0.001), contributing 17 ± 4% of the total fibroblast load in heart failure. Patients with heart failure had higher plasma levels of SDF-1 than healthy control subjects (P < 0.01). We found that cardiomyocytes constitutively secrete SDF-1, which is significantly up-regulated by angiotensin II. SDF-1 was shown to increases cardiac fibroblast migration by 59% (P < 0.05). Taken together, our data suggest that recruitment of bone marrow-derived cells under the influence of factors, including SDF-1, may play an important role in the pathogenesis of cardiac fibrosis in heart failure. (Am J Pathol 2010, 176:1735–1742; DOI: 10.2353/ajpath.2010.090574)

Heart failure (HF) is a common, disabling clinical syndrome characterized by a constellation of symptoms and signs including breathlessness and exertional intolerance. At the myocardial level, detailed echocardiographic, hemodynamic, and other imaging studies indicate that approximately half of patients presenting with HF have depressed ventricular systolic function, with the remainder seeming to have preserved systolic function. One commonality across both spectra of systolic and diastolic dysfunction is the finding of diffuse interstitial myocardial fibrosis, typically due to the deposition of collagen types I and III. Although myocardial fibrosis can have an impact on systolic function, its key sequelae on the myocardium is to increase ventricular stiffness, contributing substantially to the pathophysiology of HF.

In this context, it is widely acknowledged that myocardial fibrosis represents the balance of extracellular matrix deposition by myofibroblasts and extracellular matrix degradation by matrix metalloproteinases, which are in turn regulated by tissue inhibitors of the metalloproteinases. Traditionally, resident cardiac fibroblasts have been proposed to be the principal contributors to fibrosis, under the direction of paracrine and autocrine signals including angiotensin II, transforming growth factor β, endothelin, and connective tissue growth factor. On the other hand, other possible sources of cardiac fibroblasts have been proposed. It has been suggested that recruitment of circulating bone marrow-derived fibrocytes could contribute to the pool of fibroblasts, particularly in the context of ischemic damage. The paradigm of fibrocyte recruitment has also received particular attention in a number of noncardiovascular disorders including pulmonary fibrosis. In the cardiovascular context, in the setting of myocardial ischemia it is well known that the release of homing factors such as stromal-derived factor-1 (SDF-1) plays an important role in the trafficking of bone marrow-derived cells to the heart. However, the activity of this process in progressive heart failure, in the absence of acute ischemia, remains unknown. Other mechanisms that may contribute to the development of

Supported by the National Health and Medical Research Council of Australia.

Accepted for publication December 17, 2009.

Address reprint requests to Professor David M. Kaye, M.D., Ph.D., Heart Failure Research Group, Baker IDI Heart and Diabetes Institute, P.O. Box 6492, St. Kilda Rd. Central, Melbourne, VIC 8008, Australia. E-mail: david.kaye@bakernid.edu.au.
fibrosis in the failing heart have also been proposed, including the derivation of cardiac fibroblasts by a process of endothelial to mesenchymal cell transition.\textsuperscript{8}

On this basis of ongoing uncertainty about the mechanisms that cause myocardial fibrosis within the failing heart in the absence of acute myocardial ischemia, we aimed to investigate the hypothesis that heart failure drives a process of ongoing cardiac recruitment of bone marrow-derived circulating fibrocytes, similar to that suggested in pulmonary fibrosis. Such a mechanism would ultimately expand the pool of cardiac fibroblasts and thus myocardial fibrosis. Furthermore, we specifically investigated the role of SDF-1, given that its cognate receptor CXCR4 is known to be expressed on fibrocytes,\textsuperscript{9} and in so doing we aimed to investigate whether SDF-1 plays an important role in the pathogenesis of myocardial fibrosis. To address these questions we performed a complementary series using a mouse model (Mst1 transgenic) of dilated cardiomyopathy, isolated cardiomyocytes, and fibroblasts together with arterial and coronary sinus blood samples obtained from healthy subjects and patients with heart failure.

Materials and Methods

Animals

Twenty-four mice (12 Mst1 mice and 12 wild-type C57BL/6 mice) were used in our study. The Mst1 transgenic mice have been described in detail previously.\textsuperscript{10} In brief, Mst1 transgenic mice were generated on a C57BL/6 background, and Mst1 was overexpressed in a cardiac-specific manner using the α-myosin heavy chain promoter. Wild-type C57BL/6 mice and green fluorescent protein (GFP)-transgenic mice were obtained from Precinct Animal Centre (Baker IDI Heart and Diabetes Institute). All experimental procedures and protocols were approved by the AMREP Animal Ethics Committee, in accordance with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health.\textsuperscript{11}

Bone Marrow Transplantation and Fluorescence-Activated Cell Sorter

Bone marrow cells were harvested from 6-week-old GFP transgenic mice. Twelve mice (six C57BL/6 and six Mst1 mice aged 6 weeks) received lethal irradiation with a total dose of 11 Gy (550 rad × 2, separated by 3 hours). The remaining 12 mice did not receive irradiation. Unfractionated GFP\textsuperscript{+} bone marrow cells (5 × 10\textsuperscript{5} cells) were resuspended in serum-free medium (Dulbecco’s modified essential medium containing 0.5% penicillin-streptomycin and 1% glutamine). These cells were injected into the tail vein in a final volume of 0.2 ml. Mice were sacrificed at 13 weeks for assessment of cardiac fibrosis by Masson’s trichrome staining and GFP cell accumulation. To assess chimerism, peripheral blood cells were collected from the recipient mice at the time of sacrifice, and the frequency of GFP\textsuperscript{+} cells among peripheral nucleated blood cells was determined by fluorescence-activated cell sorter analysis using a FACS-can (BD Biosciences, Franklin Lakes, NJ). Analysis of flow cytometry data was performed using CellQuest Pro software (BD Biosciences, Franklin Lakes, NJ).

Assessment of Myocardial Bone Marrow-Derived Cell Accumulation

Mice were anesthetized with ketamine and xylazine, and the hearts were perfused with PBS solution and perfusion-fixed with 4% paraformaldehyde in PBS solution. Sliced hearts were then embedded (OCT compound, Miles Scientific, Naperville, IL) and quickly frozen in dry ice. Cryostat sections (5 μm thick) were stained with H&E. Other serial sections that were stained overnight at 4°C with anti-α-smooth muscle actin (SMA) (clone 1A4; Sigma-Aldrich, St. Louis, MO), anti-vimentin (clone GP53, Progen, Heidelberg, Germany), anti-collagen type I (Millipore Corporation, Billerica, MA), Alexa Fluor 647 anti-CCR7 (BioLegend, San Diego, CA), or anti-SDF-1α (Fitzgerald Industries International, Concord, MA) were used to evaluate the mobilization, distribution, and localization of GFP\textsuperscript{+} α-SMA\textsuperscript{−}, GFP\textsuperscript{+} vimentin\textsuperscript{−}, GFP\textsuperscript{+} collagen type I\textsuperscript{−}, CCR7\textsuperscript{−} collagen type I\textsuperscript{+}, or SDF-1α\textsuperscript{+} cells. The sections were incubated for 1 hour at room temperature with secondary antibodies that had been conjugated (Alexa Fluor 546 or Alexa Fluor 647, Molecular Probes Inc., Eugene, OR). The nuclei were stained with Hoechst 33342 (Invitrogen Australia Pty. Ltd., Mount Waverley, VIC, Australia). Slides were observed under a fluorescence microscope. The GFP signal was confirmed by staining overnight at 4°C with either monoclonal (clone 1E4) or polyclonal anti-GFP (MBL Co., Naka-ku Nagoya, Japan) antibodies. Morphometric analysis of H&E-stained tissues was performed using ImagePro Plus software (Adept Electronic Solutions Pty. Ltd., Moorabin, VIC, Australia) at a magnification of ×400. Fluorescent images were obtained using an Olympus Fluor Image Pro microscope. The quantification of GFP\textsuperscript{+} cells was performed under a microscope (magnification ×400). Ten fields of the heart tissue (left ventricle free wall, interventricular septum, and right ventricle free wall) were examined and used to calculate the number of GFP\textsuperscript{+} cells. Furthermore, the percentage of GFP\textsuperscript{+} collagen type I\textsuperscript{−} to collagen type I\textsuperscript{+} was measured under a microscope (magnification ×400). Ten fields of the heart tissue (left ventricle free wall) were examined and used to calculate the number of GFP\textsuperscript{+}/collagen I\textsuperscript{+} cells.

Cell Culture Studies

Neonatal rat ventricular cardiomyocytes were isolated from D1-3 Sprague-Dawley rats and cultured in six-well plates at a density of 250,000 cells per well as described
protein synthesis was examined by measuring the rate of 
radioactivity by liquid scintillation spectroscopy. In separate 
studies, the effect of SDF on fibroblast migration was 
determined by cell counting. To determine the effect of SDF on 
protein synthesis, 10⁵ cardiac fibroblasts (passages three to six) 
were seeded onto 24-well cell culture inserts (8-μm pore size, 
Transwell, Costar, Cambridge, MA). The lower chamber was 
filled with Dulbecco’s modified essential medium (DME) 
containing 10% fetal bovine serum (FBS) (Hyclone, Logan, 
UT). The medium was changed every other day. 3H-phenylalanine 
generated by extensive fibrosis in the left ventricle and right 
ventricle in comparison with wild-type mice (Figure 1, A–E). The use of radiation per se did not alter the extent 
of myocardial fibrosis in either Mst1 mice of the C57BL/6J 
strain. We observed a similar degree of high-level GFP 
expression in cardiac fibroblasts from wild-type and Mst1 
mice. The data were expressed as fold difference compared 
with control. 

Biochemical and Molecular Biological Assays

Plasma and conditioned media levels of SDF-1α were 
determined by a commercially available enzyme-linked 
immunosorbent assay (R&D Systems, Minneapolis, MN), 
according to the manufacturer’s instructions. Real-time 
PCR to determine SDF mRNA expression was performed in 
ventricular cardiomyocytes. Total RNA was extracted 
using the TRIzol (Invitrogen, Carlsbad, CA) purification 
system and reverse-transcribed with TaqMan reagents 
(Applied Biosystems, Foster City, CA). Real-time PCR 
using a 12.5-ng template with an ABI Prism 7700 se-
quencing system was performed with the following primers: for rat SDF (forward) 5′-TGCCCTGCGATTCTT-3′ and (reverse) 5′-GTGTGAGGTATTTCAGATGTTTG-3′ and for the housekeeping gene GAPDH (forward) 5′-ACAGCAAATCCACTCT- TCC-3′ and (reverse) 5′-GACTTCTGCTGAGTGCCC-3′. Expression values were determined by calculating the ΔΔCt value for each reaction, and data were expressed as fold difference compared with control. 

Results

Thirteen-week-old Mst1 transgenic mice were character-
ized by extensive fibrosis in the left ventricle and right 
ventricle in comparison with wild-type mice (Figure 1, A–E). The use of radiation per se did not alter the extent 
of myocardial fibrosis in either Mst1 mice of the C57BL/6J 
strain. We observed a similar degree of high-level GFP 
expression in cardiac fibroblasts from wild-type and Mst1 
mice. The data were expressed as fold difference compared 
with control. 

Bone Marrow-Derived Cells Are Recruited to the 
Nonischemic Failing Heart

To determine whether bone marrow-derived cells are 
recruited to the failing heart, in the absence of myocardial 
infarction, we developed chimeric mice by transplanting GFP+ transgenic bone 
marrow cells into wild-type and heart failure (Mst1 transgen-
ic) mice. We observed a similar degree of high-level 
GFP positivity in blood at 13 weeks in wild-type mice 
(99.9%, n = 3) and Mst1 transgenic mice (94.8%, n = 3 each group) having undergone irradiation and bone mar-
row transplantation at 6 weeks of age. As expected, 
low-efficiency GFP expression was found in wild-type 
C57BL/6 (13 weeks, 18.5%, n = 3) and Mst1 (13 weeks,
12.7%, \( n = 3 \) mice with bone marrow transplantation and no prior irradiation.

We next determined the number of GFP\(^+\) cells in the myocardium of wild-type GFP-transplanted C57BL/6 mice and GFP-transplanted Mst1 mice at 13 weeks. As shown in Figure 2, A–C, the abundance of GFP\(^+\) cells was significantly higher in the left ventricle of mice with dilated cardiomyopathy. GFP\(^+\) \( \alpha \)-SMA\(^+\) cells, which are consistent with the identification of bone marrow-derived fibroblasts, were only observed in Mst1 mice (Figure 2D), in contrast with the GFP-transplanted C57BL/6 mice in which no such cells were identified. Likewise GFP\(^+\) vimentin\(^+\) cells were also observed solely in Mst1 mice 13 weeks after irradiation and bone marrow transplantation, consistent with an origin of bone marrow-derived fibrocytic lineage (Figure 2E). These cells were also shown to stain positively for collagen I, confirming their identity as fibroblasts (data not shown).

To investigate the relative contribution of bone marrow-derived cell recruitment to the overall population of fibroblasts in the failing heart we determined the abundance of GFP\(^+\) cells as a proportion of the overall number of fibroblasts. In control hearts minimal collagen staining was observed as indicated above by Masson’s trichrome and by immunohistochemical analysis. Moreover no GFP\(^+\) collagen I\(^+\) cells were identified in C57BL/6 hearts. In Mst1 mice 16.9 ± 4.4% of cells staining positive for collagen I expressed GFP fluorescence. Taken together, these findings show that a significant fraction of fibroblasts in the myocardium of Mst1 mice arise from the bone marrow most likely via recruitment of circulating fibrocytes.

### SDF-1 Expression in Experimental Heart Failure

Given that fibrocytes are known to express CXCR4, the receptor for SDF-1, we used immunohistochemistry to evaluate the myocardial expression of SDF-1 in Mst1 mice. SDF-1 expression was readily detected in Mst1 mice compared with that in C57BL/6 mice at 13 weeks (Figure 3, A and B). This result is consistent with the hypothesis that SDF-1 may be a key homing factor in the recruitment of bone marrow cells to the heart and thus may contribute to the pathogenesis of cardiac fibrosis in nonischemic cardiomyopathy.

### Peripheral SDF Levels and Myocardial SDF Production in Healthy Subjects and Subjects with Heart Failure

The mean left ventricular ejection fraction of the HF cohort was 24 ± 2% and the average New York Heart Associa-
tion heart failure class was 2.6 ± 0.1, consistent with moderate to severe heart failure. The mean right atrial pressure was 10 ± 1 mmHg, the mean pulmonary capillary wedge pressure (PCWP) was 20.4 ± 2.9 mmHg, and the mean cardiac index was 2.2 ± 0.2 L/min/m². The plasma arterial concentration of SDF-1 was significantly higher in patients with heart failure compared with control subjects (2356 ± 138 versus 1709 ± 113 pg/ml, P = 0.01). The net transcardiac gradient (plasma coronary sinus concentration – plasma arterial concentration) for SDF for the entire HF cohort tended to be higher than that in control subjects (−31 ± 34 versus −69 ± 62 pg/ml, NS). Despite a relatively uniform left ventricular ejection fraction, the patients with HF were characterized by substantial differences in their hemodynamic parameters. When classified according to the group mean PCWP, it was evident that subjects with high PCWP demonstrated net cardiac release of SDF, which was significantly different from that in the low filling pressure group (21 ± 45 versus −118 ± 44 pg/ml, P < 0.05). In the present study we did not detect a difference in the net release of SDF-1 according to the etiology of heart failure (ischemic versus nonischemic; −27 ± 38 versus −49 ± 45 pg/ml, NS), although this conclusion was limited by the relatively small sample size. In contrast, there was a significant correlation between the transcardiac SDF gradient and the PCWP (r = 0.43, P < 0.05) (Figure 3C).

Cardiomyocyte Secretion of SDF

To assess whether cardiomyocytes exhibit the capacity to express and secrete SDF-1 we measured SDF-1 mRNA expression and protein secretion in cultured cardiac myocytes. SDF-1 mRNA was detectable in cardiomyocytes, and, in conjunction, we evaluated whether the expression of SDF-1 mRNA was modulated by neurohormones of relevance to HF. Angiotensin II caused a robust increase in SDF mRNA expression; atrial natriuretic peptide also caused a significant increase in gene expression, whereas norepinephrine was without influence (Figure 4A). Consistent with the effect on SDF gene expression, angiotensin II significantly increased the secretion of SDF-1 from cardiomyocytes, whereas norepinephrine and atrial natriuretic peptide were without effect (Figure 4B).
Influence of SDF on Cardiac Fibroblasts

We next tested the hypothesis that locally secreted SDF could act as a homing factor for fibroblasts. As demonstrated in Figure 5A, 25 nmol/L exerted a robust effect on fibroblast migration ($P < 0.05$), similar in magnitude to that induced by 100 $\mu$mol/L angiotensin II (data not shown). Of note, this effect was abolished by the selective CXCR4 receptor antagonist, AMD3100. In parallel we determined whether SDF-1 increased the rate of protein synthesis in cardiac fibroblasts. As demonstrated in Figure 5B, SDF also significantly increased the rate of $[^{3}H]$phenylalanine incorporation in fibroblasts.

Discussion

Cardiac fibrosis is a key determinant of the physiology of the myocardium in patients with symptoms of heart failure due either to systolic dysfunction or in this with heart failure with normal ejection fraction. Evidence for this association comes from histological analysis of both experimental and clinical heart failure samples or more recently from use of noninvasive imaging-based approaches in patients. In particular, the alteration in myocardial stiffness that results from myocardial fibrosis is brought about by a change in both the distribution and composition of the extracellular matrix. Together with the rate of secretion of collagen and other matrix proteins, expression of the various matrix metalloproteinases and their regulators within the myocardium ultimately determines the extracellular composition.

Given the critical role of the cardiac fibroblast in heart failure and thus for the development of anti-fibrotic strategies, it is important to understand the factors that determine the abundance and activity of these cells. Although it was previously considered that tissue fibrosis in general was the result of the activation and expansion of a pool of resident fibroblasts of mesenchymal origin, this concept has recently been challenged. Two hypotheses have been advanced, including the concept that resident cells of other lineage can differentiate into mesenchymal cells or that a pool of bone marrow-derived fibrocytes may accumulate in tissue in the presence of appropriate homing signals.

We investigated the hypothesis that under the influence of a myocardial homing signal, bone marrow-derived fibrocytes accumulate in the setting of nonischemic cardiomyopathy. To date, studies of cell accumulation in the heart have typically used myocardial infarction or ischemia/reperfusion injury as the stimulus to show recruitment of bone marrow-derived cells, including fibrocytes to the heart. This paradigm is clearly different from that of chronic cardiomyopathy and to the best of our knowledge, there have been no studies investigating whether recruitment of bone marrow cells to the heart occurs at all or what the potential attractants might be. In the present study, using the GFP-bone marrow transplant paradigm, we demonstrated for the first time that cells of bone marrow origin do accumulate in the $Mst1$ transgenic model of dilated cardiomyopathy and fully contribute to approximately one-fifth of the pool of fibroblasts in the failing fibrosed heart. We demonstrated that the GFP$^+$ cells expressed a myofibroblast phenotype characterized by staining for $\alpha$-smooth muscle actin, vimentin, or collagen. Although our study provides strong evidence for bone marrow-derived cell accumulation in the failing heart as reflected by the accumulation of GFP$^+$ cells, it is appropriate to consider the potential limitations of GFP as a cell lineage marker. In particular, recent work has highlighted the potential limitations of this approach, including variable expression of GFP in different donor cells and the possibility that the local microenvironment could alter the expression of GFP by altered gene expression. To the best of our knowledge, fibrobyte recruitment to the failing heart in the nonischemic setting has not been previously documented. Previous work has shown that acute aortic banding in normal mice can elicit the expansion of fibroblasts of bone marrow origin within the heart, probably to some extent driven by a transforming growth factor-$\beta$-mediated process. The $Mst1$ transgenic model of dilated cardiomyopathy is based on the cardiac-specific overexpression of $Mst1$, a member of the STE20 kinase family, which plays a role in the mediation of apoptosis. Although apoptosis has also been demonstrated to be relevant to the pathogenesis of human heart failure, it is not clear whether $Mst1$ per se plays a role in such a process.
Bone Marrow Derived Cells and Cardiac Fibrosis 1741

AJP April 2010, Vol. 176, No. 4

The renin-angiotensin-aldosterone axis has been ascribed a pivotal role in the pathogenesis of cardiac fibrosis in a range of cardiovascular disease states ranging from hypertension to heart failure. In particular, cell culture studies of angiotensin II have suggested that it plays a lead role as a mediator in the pathogenesis of fibrosis by promoting the differentiation of fibroblasts into myofibroblasts via a variety of signaling pathways. Interestingly, however, the evidence that angiotensin II acts alone to elicit cardiac fibrosis is not compelling. In mice subjected to pressure overload the extent of cardiac fibrosis was not mitigated in animals with angiotensin receptor type 1a knockout. Aldosterone has also been proposed to exert profibrotic effects, although its extent and mechanism remain controversial.22

Fibrocytes are bone marrow-derived cells that possess the potential to enter tissue and transition into fibroblasts, expressing a-smooth muscle actin, collagen type I, and collagen type III. In the present study we did not specifically establish whether circulating bone marrow-derived cells with a fibrocytic phenotype were detectable in blood from animals with heart failure. Given the demonstration of recruitment of fibrocytes to failing myocardium, we next considered the identity of relevant chemoattractants. Fibrocytes have been demonstrated to express a variety of chemokine receptors including CCR3, CXCR4, CCR5, and CCR7. Of these chemokines, CXCR4, the cognate receptor for SDF-1, has received particular attention with regard to its role as a putative chemoattractant in the ischemic myocardium, most notably in regard to the recruitment of bone marrow-derived cells. In their study, Abbott et al showed that antagonism of SDF-1 in the setting of cardiac injury due to ischemia reduced the recruitment of bone marrow cells in support of our study.

Cardiac fibroblasts have been previously shown to express both CXCR4 and SDF-1. In the present study we demonstrated that there was a diffuse increase in the expression of myocardial SDF-1 protein in mice with heart failure. To extend these observations further, we measured the arterial and transcardiac gradient in normal healthy individuals and those with heart failure. The peripheral plasma arterial concentration of SDF-1 was significantly higher in patients with HF. In regard to the heart specifically, we observed that in healthy individuals and patients with well controlled heart failure, there was no net cardiac release of SDF-1. However, in patients with severe heart failure and markedly elevated filling pressures there was net release of SDF-1. Although this observation does not establish a direct causal link, we have recently shown that the extent of cardiac fibrosis progressively increases as the severity of HF advances using magnetic resonance imaging. In the present study we did not perform MRI routinely as several patients already had implanted pacemaker defibrillators, and echocardiographic measures of diastolic function were not possible in a number of patients because atrial fibrillation was present.

Thus, expression of SDF-1 at levels resulting in net release from the heart might be expected to drive the recruitment of bone marrow-derived cells expressing CXCR4 receptors, including fibrocytes. Of interest, it has been previously shown that the progression of heart failure is more malignant in patients in whom the filling pressures remain substantially elevated, potentially because of the ongoing perpetuation of a profibrotic process such as that identified here. In support of this concept, we show that SDF-1 is a significant chemoattractant for cardiac fibroblasts. This concept is discordant with a study by Abbott et al, who suggested that myocardial SDF expression alone is not sufficient to recruit stem cells. This study, however, was conducted in murine normal hearts in which SDF was only transiently overexpressed via gene delivery. In our study we examined the development of fibrosis and recruitment of GFP+ cells over a prolonged period, which is a much more consistent time span relevant to the pathophysiology of heart failure. Other studies have suggested that SDF may be protective in the setting of ischemia-reperfusion injury either by promoting recruitment of angiogenic or progenitor stem cells.

Our studies clearly showed that the failing myocardium and cardiomyocytes express and can secrete SDF. Although in the normal human heart we did not detect "release" of SDF, it is relevant to consider that net release represents the combination of local release and extraction (including binding and degradation). Myocardial SDF-1 levels are known to increase after myocardial infarction, with concomitant increases in the rate of bone marrow-derived cardiac progenitor cells. In the present study we showed that angiotensin II promoted the secretion of SDF-1 by cardiac myocytes. Previously it has been shown that angiotensin II exerts a pro-angiogenic effect, possibly mediated by factors such as vascular endothelial growth factor and basic fibroblast growth factor. Moreover, myocardial stretch is known to result in the release of growth factors and hormones, including angiotensin II, from cardiomyocytes, perhaps contributing to autocrine myocardial release of SDF-1.

In the present study we aimed to evaluate the role of SDF-1 as a contributor to myocardial fibrosis in the setting of chronic heart failure, which has not been studied previously. Our data support the notion that elevated SDF-1 expression may contribute to bone marrow cell recruitment and fibrosis of the failing heart. We did not directly test the effect of SDF-1 antagonism in our murine model to demonstrate the amelioration of fibrocyte recruitment; however, our findings are consistent with previous studies in which SDF-1 expression was altered by acute ischemia. In the context of heart failure we demonstrated SDF-1 release by isolated cardiomyocytes in the presence of neurohormonal stimulation and from the failing human heart. Finally we documented a chemoattractant effect of SDF-1 on cardiac fibroblasts. These observations, therefore, lay the foundation for the further development of antifibrotic strategies in heart failure.

Acknowledgment

We gratefully acknowledge the expert technical assistance of Mr. Peter Kanellakis.
References